elranatamab
pfizer
['mmsm', 'magnetismm-3', 'multiple myeloma', 'elranatamab']
patients with penta- or triple-class refractory multiple myeloma in cohort a the open-label phase 2 magnetismm-3 study elicited an orr by bicr of 61.0% on treatment with the cd3/bcma bispecific antibody elranatamab. #ash22 #mmsm | 
Oncology news and insights from leading researchers and cancer centers.